10:48 AM EST - ProMIS Neurosciences, Inc. : Announced today an outline of its strategic priorities and action plan for 2021. The priorities for 2021 fall into four key areas: Near-term focus on rare neurodegenerative diseases, especially ALS; Use of proprietary platform to support portfolio expansion; PMN310 antibody lead program for Alzheimer’s disease; COVID-19, further progress on serological assays. ProMIS Neurosciences, Inc.
shares T.PMN are trading unchanged at $0.10.
